The bronchodilator and cardiovascular activity of isoproterenol hydrochloride (Isuprel) 5.0 mg, Salbutamol 5.0 and 2.5 mg and saline administered by IPPB to 30 patients with chronic bronchial asthma were determined and compared. Equal doses of isoproterenol and Salbutamol had similar peak bronchodilator effect, but the peak effect was reached much earlier with isoproterenoL Salbutamol bad longer and more persistent bronchodilator activity without any appreciable increase in heart rate; rather, a decrease hi heart rate ensued at the height of the bronchodilator activity. The bronchodilator activity of Salbutamol is dose dependent. While 5.0 mg Saihutainol showed a more prominent bronchodilator activity, 2.5 mg Salbutamol was better tolerated. It was concluded that Salbutainol, at a dose of 2.5 to 5.0 mg administered in the form of an aerosol by LPPB, provides a more usefut short term treatment of asthma than isoproterenoL Sal tamO a new beta adrenergic receptor stimulant, is widely used in Western Europe in the form of pressurized inhalant and orally administered tablets in the management of chronic asthma.
The bronchodilator and cardiovascular activity of isoproterenol hydrochloride (Isuprel) 5.0 mg, Salbutamol 5.0 and 2.5 mg and saline administered by IPPB to 30 patients with chronic bronchial asthma were determined and compared. Equal doses of isoproterenol and Salbutamol had similar peak bronchodilator effect, but the peak effect was reached much earlier with isoproterenoL Salbutamol bad longer and more persistent bronchodilator activity without any appreciable increase in heart rate; rather, a decrease hi heart rate ensued at the height of the bronchodilator activity. The bronchodilator activity of Salbutamol is dose dependent. While 5.0 mg Saihutainol showed a more prominent bronchodilator activity, 2.5 mg Salbutamol was better tolerated. It was concluded that Salbutainol, at a dose of 2.5 to 5.0 mg administered in the form of an aerosol by LPPB, provides a more usefut short term treatment of asthma than isoproterenoL Sal tamO a new beta adrenergic receptor stimulant, is widely used in Western Europe in the form of pressurized inhalant and orally administered tablets in the management of chronic asthma.
Salbutamol, which combines a selective and potent action on the bronchial beta receptors with minimal cardiovascular stimuIation,2 would appear suitable for aerosolization in nebulizers powered by compressed air, oxygen, handbulbs, electrical compressors and IPPB machines.
This study compares the bronchodilator and cardiovascular activity of Salbutamol, isoproterenol (Isuprel) and a placebo (saline) in solution form administered by IPPB.
The study was designed in three path. In the first part, Salbutamol 5 mg and isoproterenol 5 mg were administered by inhalation on two consecutive days respectively to ten asthmatic patients. In the second part, 2.5 mg of Satbutamol only was administered by inhalation to ten asthmatic patients and in the third part, I ml of saline was similarly admrnistered to ten asthmatic patients. Since all solutions were administered in equal quantities, the amount of aerosol wasted was identical in all patients. The above mentioned doses of drug administered represent, therefore, the upper limit of the dose. The purpose of the study was explained to the patients of group I who were requested to express their preference for one of the two drugs.
MATERIAL (Table 1) Thirty consecutive patients from the pulmonary outpatient clinic suffering from chronic asthma, with proved reversible airway obstruction were selected. They were divided into CHEST, VOL.62, NO. 3, SEPTEMBER, 1972 274 SPITZER, GOLDSCHMIDT AND DUBRAWSKY (Fig land 2) .
Following administration of the aerosol the mean heart rate diminished gradually through the first hour and remained significantly lower throughout the four hour period (Fig 3) . No change was noted in systolic, diastolic or pulse pressure (Fig 4) . Four patients manifested side-effects in the form of mild tremor (2) and headache (2). h) Isoproterenol, 5 mg The mean initial FEy, percent and FVC percent were 3.3 percent and 61 percent respectively. These increased significantly (P<0.0O1) within five minutes and reached a peak value of 63 percent and 98 Percent respectively within the first ten minutes of administration. There was a net peak mean increase in FEV percent and FVC percent of 30 percent and 37 percent respectively. These measurements declined rapidly and reached approximately the initial value by 180 minutes (Fig 1 and 2) . However, in two patients the FEy, percent and in six patients the FVC percent values were significantly below the initial values at 240 minutes. The mean heart rate increased significantly during the first ten minutes and then diminished gradually to below initial values at 60 minutes (Fig 3) . No significant change in systolic and diastolic pressures was observed; however, a slight increase in pulse pressure was noted in this group (Fig 4) . Six patients manifested one or more side-effects consisting of palpitations (four), headaches (two), tremor (two) and dizziness (one).
Group II
Salbutamol, 2.5mg
The mean FEy, percent and FVC percent were 43 percent and 68 percent respectively. These increased significantly (P<0.01) within five minutes and reached a peak value of 63 percent and 98 percent at 60 minutes respectively. There was a net peak mean increase in FEV percent and FVC percent of 20 percent and 30 percent respectively (Fig 1 and 2) . The mean increase at 240 minutes was still 12 percent and 16 percent higher respectively than the initial value (p<O.Ql) (Fig 1, 2) .
The mean heart rate, systolic, diastolic and pulse pressure behaved similarly to those in the 5 mg Salbutamol group (Fig 3 and 4) .
GroupIII
Placebo group No significant change in FEy, percent, percent, heart rate, systolic, diastolic and 
Cornpari.ion of Groups
1. Salbutamol 5.0 mg vs isoproterenol 5.0 mg. The mean percent increase in FEy, percent and FVC percent was initially similar in both groups. The decline in both parameters in the isoproterenol group occurred rapidly after ten minutes, while in the Salbutamol group the increase in these parameters was maintained up to 120 minutes. This difference was significant (P<0.05) from 60 minutes after the medication was given (Fig 1 and 2) . The heart rate in the isoproterenol group was significantly higher than in the Salbutamol group for the first ten minutes (P< 0.05) (Fig 3) . There were no significant differences in blood pressure (Fig 4) .
2. Salbutamol 2.5mg vs isoproterenol 5.0 mg. The mean percent increase in FEy, percent was initially greater in the isoproterenol group. However the increase was more prolonged in the Salbutamol group and from 180 minutes, the difference was significant (P<0.05) (Fig 1) . The mean percent increase in FVC percent was greater in the isoproterenol group up to 60 minutes. From then, a significant difference (P<0.05) in the two groups, in favor of Salbutamol, was noted (Fig 2) . The differences in heart rate were similar to those described previously.
3. Salbutamol 5.0 mg vs Salbutamol 2.5 mg.
The mean percent increase in FEV percent and FVC percent was significantly greater up to the 60 minutes point in the 5.0 mg Salbutamol group. From then on the decline in the 5 mg group was steeper and the difference between the two became insignificant (Fig 1 and 2) . No difference in heart rate and blood pressure was noted between the two groups.
Patients' Preference Nine out of ten patients in group I preferred Salbutamol over isoproterenol. The reasons given by the patients for this preference were: lack of palpitations and longer lasting relief. One patient did not prefer either drug.
DISCUSSION
It has been shown that the responses of patients receiving 5 mg isoproterenol and 5 mg Salbutamol are equal in respect to peak bronchodilating effect but the peak effect was reached much earlier with isoproterenol. Salbutamol has, however, the distinct advantage over isoproterenol in its longer and more persistent bronchodilator activity, without having the rebound bronchoconstriction seen following the subsidence of the isoproterenol effect.
Isoproterenol had a significant initial effect on heart rate which lasted approximately 30 minutes while Salbutamol at this dose did not cause an increase in heart rate. Rather a decrease in heart rate followed the point when peak bronchodilating effect was observed. No significant effect on blood pressure of either was noted.
The side-effects following inhalation of each of the drugs were similar except for the prominence of palpitation after isoproterenol.
From the comparison of the two Salbutamol doses it was concluded that the 5 mg dose was more effective in respect to peak bronchodilating effect and total effect during the first one to two hours. Thereafter, no advantage in the higher dose was noted. The side-effects noted with the 5 mg Salbutamol dose (tremor and headache) were not observed with the 2.5 mg dose. No cardiovascular activity was noted with the doses administered in this trial.
It
can be concluded that Salbutamol, administered in the form of an aerosol, is an effective beta adrenergic stimulant with potent and long persistent bronchodilating activity. The response to isoproterenol was more rapid. The response to Salbutamol, though less rapid in action, demonstrated more persistent effects. Salbutamol can be used with great advantage in the form of an aerosol administered by a powered nebulizer or IPPB in patients with asthma,#{176} at a dose of 2.5 to 5.0 mgrn. It can be used freely in most patients where isoproterenol must be used with caution (heart disease, hypertension, etc).
In testing the bronchodilator responsiveness of patients in the pulmonary function laboratory, it has to be remembered that the peak bronchodilating effect of Salbutamol is reached at 30 minutes. 
